COVID-19 vaccine effectiveness
If you want to see all comparisons, please click here
SARS-CoV-2 strain WIV04 vs Placebo
You will find below the forest plots for this comparison with the general characteristics and risk of bias assessment for all RCTs identified.
Of note all trials may not be included in the synthesis.
|Trial||Type||Comparisons||Design||Participants||Sample size||Overall risk
|Intervention 1||Intervention 2|
Sinopharm - China National Biotec Group Company Limited
Al Kaabi N, JAMA, 2021
|RCTPhase 3||Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain||N=40411||
For risk of bias assessment, we are considering the “effect of assignment to intervention” which might not be the analysis planned and reported by investigators. Consequently, when investigators planned to assess and report the “per-protocol” effect, the risk of bias for domain 2 may be evaluated as “some concerns”. We will contact investigators to obtain the results of the intent-to-treat analysis.